The Recent Development in the Diagnosis of Mycobacterium tuberculosis

Abstract

Mycobacterium tuberculosis (MTB) remains a global health issue and continues to rank among the leading causes of death from infectious diseases worldwide. Its persistence is primarily attributed to the microorganism's challenging and time-consuming diagnosis and treatment, which drives the need for new diagnostic tests. The development of rapid, highly sensitive point-of-care (POC) tests is crucial, as these tests address the limitations of traditional methods, which are lengthy and exhibit low sensitivity. Early and rapid diagnostic tests ensure timely diagnoses and treatments for individuals while playing a pivotal role in preventing the spread of MTB and curbing societal transmission. These diagnostic tests significantly impact TB diagnosis and treatment, potentially breaking the chain of transmission and presenting a promising step toward combating the infection. Rapid and accurate diagnostic tests for MTB detection continue to attract significant attention in the literature and show promise for widespread application. However, they face challenges such as limited accessibility and usability, particularly in underdeveloped countries. The implementation of rapid tests requires careful consideration of time and resource efficiency compared with traditional tests. This study reviews the diagnostic tests developed for MTB detection, tracing their evolution from the past to the present.

Keywords

diagnosis / Mycobacterium tuberculosis / rapid test

References

[1] Global Tuberculosis Report 2023 (World Health Organization, 2023).

[2] Methods Used By WHO To Estimate The Global Burden of TB Disease (World Health Organization, 2021).

[3] X. Zhang, Y. Tian, Y. Shi, et al., “Naked-Eye LAMP Assay of M. tuberculosis in Sputum by In Situ Au Nanoprobe Identification: For the In Vitro Diagnostics of Tuberculosis,” ACS Infectious Diseases 10 (2024): 2668–2678.

[4] R. Brosch, S. V. Gordon, M. Marmiesse, et al., “A New Evolutionary Scenario for the Mycobacterium tuberculosis Complex,” Proceedings of the National Academy of Sciences 99 (2002): 3684–3689.

[5] S. T. Cole, R. Brosch, J. Parkhill, et al., “Deciphering the Biology of Mycobacterium tuberculosis From the Complete Genome Sequence,” Nature 393 (1998): 537–544.

[6] M. M. Bigi, M. A. Forrellad, J. S. García, F. C. Blanco, C. L. Vázquez, and F. Bigi, “An Update on Mycobacterium tuberculosis Lipoproteins,” Future Microbiology 18 (2023): 1381–1398.

[7] B. P. Kelly, S. K. Furney, M. T. Jessen, and I. M. Orme, “Low-Dose Aerosol Infection Model for Testing Drugs for Efficacy Against Mycobacterium tuberculosis,” Antimicrobial Agents and Chemotherapy 40 (1996): 2809–2812.

[8] A. N. Leung, “Pulmonary Tuberculosis: The Essentials,” Radiology 210 (1999): 307–322.

[9] I. Smith, “Mycobacterium tuberculosis Pathogenesis and Molecular Determinants of Virulence,” Clinical Microbiology Reviews 16 (2003): 463–496.

[10] R. D. Turner and G. H. Bothamley, “Cough and the Transmission of Tuberculosis,” Journal of Infectious Diseases 211 (2015): 1367–1372.

[11] S. D. Shi, P. R. Hsueh, P. C. Yang, and C. C. Chou, “Use of DosR Dormancy Antigens From Mycobacterium tuberculosis for Serodiagnosis of Active and Latent Tuberculosis,” ACS Infectious Diseases 6 (2019): 272–280.

[12] U. Tansuphaisiri and B. Kladphuang, “Evaluation of Sputum Staining by Modified Cold Method and Comparison With Ziehl-Neelsen and Fluorochrome Methods for the Primary Diognosis of Tuberculosis,” Southeast Asian Journal of Tropical Medicine and Public Health 33 (2002): 128–135.

[13] C. Abe, “Standardization of Laboratory Tests for Tuberculosis and Their Proficiency Testing,” Kekkaku 78 (2003): 541–551.

[14] J. Kim, M. Jang, K. G. Lee, et al., “Plastic-Chip-Based Magnetophoretic Immunoassay for Point-of-Care Diagnosis of Tuberculosis,” ACS Applied Materials & Interfaces 8 (2016): 23489–23497.

[15] Y. J. Ryu, “Diagnosis of Pulmonary Tuberculosis: Recent Advances and Diagnostic Algorithms,” Tuberculosis and Respiratory Diseases 78 (2015): 64–71.

[16] R. Loddenkemper, M. Lipman, and A. Zumla, “Clinical Aspects of Adult Tuberculosis,” Cold Spring Harbor Perspectives in Medicine 6 (2016): a017848.

[17] L. Muñoz, H. R. Stagg, and I. Abubakar, “Diagnosis and Management of Latent Tuberculosis Infection: Table 1,” Cold Spring Harbor Perspectives in Medicine 5 (2015): a017830.

[18] D. Brodie and N. W. Schluger, “The Diagnosis of Tuberculosis,” Clinics in Chest Medicine 26 (2005): 247–271.

[19] T. A. Campelo, P. R. Cardoso de Sousa, L. L. Nogueira, C. C. Frota, and P. R. Zuquim Antas, “Revisiting the Methods for Detecting Mycobacterium tuberculosis: What Has the New Millennium Brought Thus Far?,” Access Microbiology 3 (2021): 000245.

[20] D. A. Moore, C. A. Evans, R. H. Gilman, et al., “Microscopic-Observation Drug-Susceptibility Assay for the Diagnosis of TB,” New England Journal of Medicine 355 (2006): 1539–1550.

[21] N. S. Shah, P. Moodley, P. Babaria, et al., “Rapid Diagnosis of Tuberculosis and Multidrug Resistance by the Microscopic-Observation Drug-Susceptibility Assay,” American Journal of Respiratory and Critical Care Medicine 183 (2011): 1427–1433.

[22] Y. Boum, P. Orikiriza, G. Rojas-Ponce, et al., “Use of Colorimetric Culture Methods for Detection of Mycobacterium tuberculosis Complex Isolates From Sputum Samples in Resource-Limited Settings,” Journal of Clinical Microbiology 51 (2013): 2273–2279.

[23] A. Gupta, M. R. Sen, T. M. Mohapatra, and S. Anupurba, “Evaluation of the Performance of Nitrate Reductase Assay for Rapid Drug-Susceptibility Testing of Mycobacterium tuberculosis in North India,” Journal of Health, Population, and Nutrition 29 (2011): 20–25.

[24] P. Chen, Y. Meng, T. Liu, et al., “Sensitive Urine Immunoassay for Visualization of Lipoarabinomannan for Noninvasive Tuberculosis Diagnosis,” ACS Nano 17 (2023): 6998–7006.

[25] P. Chen, M. Shi, G. D. Feng, et al., “A Highly Efficient Ziehl-Neelsen Stain: Identifying De Novo Intracellular Mycobacterium tuberculosis and Improving Detection of Extracellular M. tuberculosis in Cerebrospinal Fluid,” Journal of Clinical Microbiology 50 (2012): 1166–1170.

[26] G. Theron, R. Venter, G. Calligaro, et al., “Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?,” Clinical Infectious Diseases 62 (2016): 995–1001.

[27] Y. R. Ngangue, C. Mbuli, A. Neh, et al., “Diagnostic Accuracy of the Truenat MTB Plus Assay and Comparison With the Xpert MTB/RIF Assay to Detect Tuberculosis Among Hospital Outpatients in Cameroon,” Journal of Clinical Microbiology 60 (2022): e00155-22.

[28] O. P. R. Balisan, J. R. T. Galamay, L. N. Cale-Subia, and A. M. De Luna, “Utility of Nucleic Acid Amplification Test in the Detection of Tuberculosis in Biological Fluids From Suspected TB Patients in a Cardiovascular Center in the Philippines,” Acta Tropica 249 (2024): 107078.

[29] L. R. Inbaraj, J. Daniel, M. K. Sathya Narayanan, et al., “TB-LAMP (Loop-Mediated Isothermal Amplification) for Diagnosing Pulmonary Tuberculosis in Children,” Cochrane Database of Systematic Reviews 2023 (2023): CD015806.

[30] N. Zaporojan, R. A. Negrean, R. Hodișan, C. Zaporojan, A. Csep, and D. C. Zaha, “Evolution of Laboratory Diagnosis of Tuberculosis,” Clinics and Practice 14 (2024): 388–416.

[31] R. P. Mahato and S. Kumar, “The Future in Diagnostic Tools for TB Outbreaks: A Review of the Approaches With Focus on LAMP and RPA Diagnostics Tests,” Journal of Microbiological Methods 227 (2024): 107064.

[32] L. R. Inbaraj, J. Daniel, P. Rajendran, et al., “Truenat MTB Assays for Pulmonary Tuberculosis and Rifampicin Resistance in Adults,” Cochrane Database of Systematic Reviews 2023 (2023): CD015543.

[33] Y. C. Yang, P. L. Lu, S. C. Huang, Y. S. Jenh, R. Jou, and T. C. Chang, “Evaluation of the Cobas TaqMan MTB Test for Direct Detection of Mycobacterium tuberculosis Complex in Respiratory Specimens,” Journal of Clinical Microbiology 49 (2011): 797–801.

[34] R. L. Guerra, N. M. Hooper, J. F. Baker, et al., “Use of the Amplified Mycobacterium tuberculosis Direct Test in a Public Health Laboratory,” Chest 132 (2007): 946–951.

[35] M. Pai, S. Kalantri, and K. Dheda, “New Tools and Emerging Technologies for the Diagnosis of Tuberculosis: Part II. Active Tuberculosis and Drug Resistance,” Expert Review of Molecular Diagnostics 6 (2006): 423–432.

[36] T. Notomi, Y. Mori, N. Tomita, and H. Kanda, “Loop-mediated Isothermal Amplification (LAMP): Principle, Features, and Future Prospects,” Journal of Microbiology 53 (2015): 1–5.

[37] Y. P. Wong, S. Othman, Y. L. Lau, S. Radu, and H. Y. Chee, “Loop-Mediated Isothermal Amplification (LAMP): A Versatile Technique for Detection of Micro-organisms,” Journal of Applied Microbiology 124 (2018): 626–643.

[38] “Nationwide Shortage of Tuberculin Skin Test Antigens: CDC Recommendations for Patient Care and Public Health Practice,” Morbidity and Mortality Weekly Report 68 (2019): 552–553.

[39] R. A. Pennie, “Mantoux Tests. Performing, Interpreting, and Acting Upon Them,” Canadian Family Physician 41 (1995): 1025–1029.

[40] A. A. Lardizabal and L. B. Reichman, “Diagnosis of Latent Tuberculosis Infection,” Microbiology Spectrum 5 (2017): TNMI7-0019-2016.

[41] R. E. Huebner, M. F. Schein, and J. B. Bass., “The Tuberculin Skin Test,” Clinical Infectious Diseases 17 (1993): 968–975.

[42] P. L. Lin, S. Pawar, A. Myers, et al., “Early Events in Mycobacterium tuberculosis Infection in Cynomolgus Macaques,” Infection and Immunity 74 (2006): 3790–3803.

[43] W. Bae, K. U. Park, E. Y. Song, et al., “Comparison of the Sensitivity of QuantiFERON-TB Gold In-Tube and T-SPOT.TB According to Patient Age,” PLoS ONE 11 (2016): e0156917.

[44] G. H. Mazurek, J. Jereb, P. LoBue, M. F. Iademarco, B. Metchock, and A. Vernon, “Guidelines for Using the QuantiFERON®-TB Gold Test for Detecting Mycobacterium tuberculosis Infection, United States,” Morbidity and Mortality Weekly Report Recommendations and Reports 54 (2005): 49–55.

[45] T. Kurenuma, I. Kawamura, H. Hara, et al., “The RD1 Locus in the Mycobacterium tuberculosis Genome Contributes to Activation of Caspase-1 via Induction of Potassium Ion Efflux in Infected Macrophages,” Infection and Immunity 77 (2009): 3992–4001.

[46] S. Daugelat, J. Kowall, J. Mattow, et al., “The RD1 Proteins of Mycobacterium tuberculosis: Expression in Mycobacterium smegmatis and Biochemical Characterization,” Microbes and Infection 5 (2003): 1082–1095.

[47] A. Shafeque, J. Bigio, C. A. Hogan, M. Pai, and N. Banaei, “Fourth-Generation QuantiFERON-TB Gold Plus: What Is the Evidence?,” Journal of Clinical Microbiology 58 (2020): e01950-19.

[48] Y. Ma, R. Li, J. Shen, et al., “Clinical Effect of T-SPOT.TB Test for the Diagnosis of Tuberculosis,” BMC Infectious Diseases 19 (2019): 993.

[49] The Use of Lateral Flow Urine Lipoarabinomannan Assay (LF-LAM) for the Diagnosis and Screening of Active Tuberculosis in People Living With HIV: Policy Guidance (World Health Organization, 2015).

[50] J. Peter, G. Theron, D. Chanda, et al., “Test Characteristics and Potential Impact of the Urine LAM Lateral Flow Assay in HIV-Infected Outpatients Under Investigation for TB and Able to Self-Expectorate Sputum for Diagnostic Testing,” BMC Infectious Diseases 15 (2015): 262.

[51] A. Benjamin, S. C. Cavalcante, L. F. Jamal, et al., “Accuracy of Determine TB-LAM Ag to Detect TB in HIV Infected Patients Associated With Diagnostic Methods Used in Brazilian Public Health Units,” PLoS One 14 (2019): e0221038.

[52] S. Singh, I. Saraav, and S. Sharma, “Immunogenic Potential of Latency Associated Antigens Against Mycobacterium tuberculosis,” Vaccine 32 (2014): 712–716.

[53] I. Latorre and J. Domínguez, “Dormancy Antigens as Biomarkers of Latent Tuberculosis Infection,” EBioMedicine 2 (2015): 790–791.

[54] K. Dheda, M. Ruhwald, G. Theron, J. Peter, and W. C. Yam, “Point-Of-Care Diagnosis of Tuberculosis: Past, Present and Future,” Respirology 18 (2013): 217–232.

[55] A. L. García-Basteiro, A. Dinardo, B. Saavedra, et al., “Point of Care Diagnostics for Tuberculosis,” Pulmonology 24 (2018): 73–85.

[56] J. M. Hong, H. Lee, N. V. Menon, C. T. Lim, L. P. Lee, and C. W. Ong, “Point-Of-Care Diagnostic Tests for Tuberculosis Disease,” Science Translational Medicine 14 (2022): eabj4124.

[57] A. K. Gupta, A. Singh, and S. Singh, “ Diagnosis of Tuberculosis: Nanodiagnostics Approaches,” in NanoBioMedicine, ed. S. K. Saxena and S. M. P. Khurana (Springer, 2020), 261–283.

[58] C. Celik, N. Ildiz, M. Z. Kaya, A. B. Kilic, and I. Ocsoy, “Preparation of Natural Indicator Incorporated Media and its Logical Use as a Colorimetric Biosensor for Rapid and Sensitive Detection of Methicillin-Resistant Staphylococcus aureus,” Analytica Chimica Acta 1128 (2020): 80–89.

[59] C. Celik, N. Ildiz, P. Sagiroglu, M. A. Atalay, C. Yazici, and I. Ocsoy, “Preparation of Nature Inspired Indicator Based Agar for Detection and Identification of MRSA and MRSE,” Talanta 219 (2020): 121292.

[60] C. Celik, N. Y. Demir, M. Duman, N. Ildiz, and I. Ocsoy, “Red Cabbage Extract-Mediated Colorimetric Sensor for Swift, Sensitive and Economic Detection of Urease-Positive Bacteria by Naked Eye and Smartphone Platform,” Scientific Reports 13 (2023): 2056.

[61] C. Celik, G. Can Sezgin, U. G. Kocabas, et al., “Novel Anthocyanin-Based Colorimetric Assay for the Rapid, Sensitive, and Quantitative Detection of Helicobacter pylori,” Analytical Chemistry 93 (2021): 6246–6253.

[62] C. Celik, G. Kalin, Z. Cetinkaya, N. Ildiz, and I. Ocsoy, “Recent Advances in Colorimetric Tests for the Detection of Infectious Diseases and Antimicrobial Resistance,” Diagnostics 13 (2023): 2427.

[63] G. Can Sezgin, Y. E. Tekin, B. Calim, et al., “Development of a Colorimetric Urease Test Based on Au NPS Capped With Anthocyanin for the Rapid Detection of Helicobacter pylori Through Multiple Readouts,” ChemistrySelect 8 (2023): e202300637.

[64] M. I. Shukoor, M. O. Altman, D. Han, et al., “Aptamer-Nanoparticle Assembly for Logic-Based Detection,” ACS Applied Materials & Interfaces 4 (2012): 3007–3011.

[65] T. T. Tsai, C. Y. Huang, C. A. Chen, et al., “Diagnosis of Tuberculosis Using Colorimetric Gold Nanoparticles on a Paper-Based Analytical Device,” ACS Sensors 2 (2017): 1345–1354.

[66] S. Nandini, S. Nalini, S. Bindhu, et al., “ Current Trends of Functionalized Nanomaterial-Based Sensors in Point-Of-Care Diagnosis,” in Functionalized Nanomaterial-Based Electrochemical Sensors, ed. C. M. Hussain and J. G. Manjunatha (Woodhead Publishing, 2022), 337–353

[67] J. Ma, M. Du, C. Wang, et al., “Rapid and Sensitive Detection of Mycobacterium tuberculosis by an Enhanced Nanobiosensor,” ACS Sensors 6 (2021): 3367–3376.

[68] J. Kim, V. T. Tran, S. Oh, et al., “Clinical Trial: Magnetoplasmonic ELISA for Urine-Based Active Tuberculosis Detection and Anti-tuberculosis Therapy Monitoring,” ACS Central Science 7 (2021): 1898–1907.

[69] Y. Wang, L. Yu, X. Kong, and L. Sun, “Application of Nanodiagnostics in Point-Of-Care Tests for Infectious Diseases,” International Journal of Nanomedicine 12 (2017): 4789–4803.

[70] M. Cordeiro, F. Ferreira Carlos, P. Pedrosa, A. Lopez, and P. V. Baptista, “Gold Nanoparticles for Diagnostics: Advances Towards Points of Care,” Diagnostics 6 (2016): 43.

[71] Y. Gupta and A. S. Ghrera, “Recent Advances in Gold Nanoparticle-Based Lateral Flow Immunoassay for the Detection of Bacterial Infection,” Archives of Microbiology 203 (2021): 3767–3784.

[72] X. He, T. Hao, H. Geng, et al., “Sensitization Strategies of Lateral Flow Immunochromatography for Gold Modified Nanomaterials in Biosensor Development,” International Journal of Nanomedicine 18 (2023): 7847–7863.

[73] X. Z. Mou, X. Y. Chen, J. Wang, et al., “Bacteria-Instructed Click Chemistry Between Functionalized Gold Nanoparticles for Point-of-Care Microbial Detection,” ACS Applied Materials & Interfaces 11 (2019): 23093–23101.

[74] D. Cam and H. A. Öktem, “Optimizations Needed for Lateral Flow Assay for Rapid Detection of Pathogenic E. Coli,” Turkish Journal of Biology 41 (2017): 954–968.

[75] Y. Xianyu, Q. Wang, and Y. Chen, “Magnetic Particles-Enabled Biosensors for Point-Of-Care Testing,” TrAC Trends in Analytical Chemistry 106 (2018): 213–224.

[76] S. Sahoo, A. Nayak, A. Gadnayak, et al., “Quantum Dots Enabled Point-of-Care Diagnostics: A New Dimension to the Nanodiagnosis,” in Advanced Nanomaterials for Point of Care Diagnosis and Therapy, ed. S. Dave, J. Das, and S. Ghosh (Elseiver, 2022), 43–52

[77] F. Beck, M. Loessl, and A. J. Baeumner, “Signaling Strategies of Silver Nanoparticles in Optical and Electrochemical Biosensors: Considering Their Potential for the Point-Of-Care,” Microchimica Acta 190 (2023): 91.

[78] S. Roy, F. Arshad, S. Eissa, et al., “Recent Developments Towards Portable Point-of-Care Diagnostic Devices for Pathogen Detection,” Sensors & Diagnostics 1 (2022): 87–105.

[79] X. Yang, X. Chen, J. Huang, et al., “Ultrafast, One-step, Label-Based Biosensor Diagnosis Platform for the Detection of Mycobacterium tuberculosis in Clinical Applications,” ACS Infectious Diseases 9 (2023): 762–772.

[80] M. M. Hussain, T. M. Samir, and H. M. Azzazy, “Unmodified Gold Nanoparticles for Direct and Rapid Detection of Mycobacterium tuberculosis Complex,” Clinical Biochemistry 46 (2013): 633–637.

[81] N. Patnaik and R. J. Dey, “Label-Free Citrate-Stabilized Silver Nanoparticles-Based, Highly Sensitive, Cost-Effective, and Rapid Visual Method for the Differential Detection of Mycobacterium tuberculosis and Mycobacterium Bovis,” ACS Infectious Diseases 10 (2023): 426–435.

[82] C. Sun, X. Zhang, J. Wang, Y. Chen, and C. Meng, “Novel Mesoporous Silica Nanocarriers Containing Gold; a Rapid Diagnostic Tool for Tuberculosis,” BMC Complementary Medicine and Therapies 21 (2021): 277.

[83] B. Zhou, M. Zhu, Y. Hao, and P. Yang, “Potential-Resolved Electrochemiluminescence for Simultaneous Determination of Triple Latent Tuberculosis Infection Markers,” ACS Applied Materials & Interfaces 9 (2017): 30536–30542.

[84] High-Priority Target Product Profiles for New Tuberculosis Diagnostics: Report of A Consensus Meeting (World Health Organization, 2014).

[85] E. Kamra, T. Prasad, A. Rais, et al., “Diagnosis of Genitourinary Tuberculosis: Detection of Mycobacterial Lipoarabinomannan and MPT-64 Biomarkers Within Urine Extracellular Vesicles by Nano-Based Immuno-PCR Assay,” Scientific Reports 13 (2023): 11560.

[86] B. B. Oliveira, B. Veigas, and P. V. Baptista, “Isothermal Amplification of Nucleic Acids: The Race for the Next ‘Gold Standard’,” Frontiers in Sensors 2 (2021): 752600.

[87] W. Liu, D. Zou, X. He, et al., “Development and Application of a Rapid Mycobacterium tuberculosis Detection Technique Using Polymerase Spiral Reaction,” Scientific Reports 8 (2018): 3003.

[88] O. Hu, Z. Li, J. Wu, Y. Tan, Z. Chen, and Y. Tong, “A Multicomponent Nucleic Acid Enzyme-Cleavable Quantum Dot Nanobeacon for Highly Sensitive Diagnosis of Tuberculosis With the Naked Eye,” ACS Sensors 8 (2023): 254–262.

[89] D. R. Martin, N. R. Sibuyi, P. Dube, et al., “Aptamer-Based Diagnostic Systems for the Rapid Screening of TB at the Point-of-Care,” Diagnostics 11 (2021): 1352.

[90] S. Lavania, R. Das, A. Dhiman, et al., “Aptamer-Based TB Antigen Tests for the Rapid Diagnosis of Pulmonary Tuberculosis: Potential Utility in Screening for Tuberculosis,” ACS Infectious Diseases 4 (2018): 1718–1726.

[91] S. K. Gurmessa, L. T. Tufa, J. Kim, et al., “Colorimetric Detection of Mycobacterium tuberculosis ESX-1 Substrate Protein in Clinical Samples Using Au@Pd Nanoparticle-Based Magnetic Enzyme-Linked Immunosorbent Assay,” ACS Applied Nano Materials 4 (2020): 539–549.

[92] H. Li, D. Li, H. Chen, et al., “Application of Silicon Nanowire Field Effect Transistor (SiNW-FET) Biosensor With High Sensitivity,” Sensors 23 (2023): 6808.

[93] W. Y. N. Naing and Z. Z. Htike, “Advances in Automatic Tuberculosis Detection in Chest X-Ray Images,” Signal & Image Processing 5 (2014): 41.

[94] R. Hooda, S. Sofat, S. Kaur, A. Mittal, and F. Meriaudeau, “Deep-Learning: A Potential Method for Tuberculosis Detection Using Chest Radiography,” in IEEE International Conference on Signal and Image Processing Applications (ICSIPA), (IEEE, 2017), 497–502.

[95] P. Lakhani and B. Sundaram, “Deep Learning at Chest Radiography: Automated Classification of Pulmonary Tuberculosis by Using Convolutional Neural Networks,” Radiology 284 (2017): 574–582.

[96] Y. Zhan, Y. Wang, W. Zhang, B. Ying, and C. Wang, “Diagnostic Accuracy of the Artificial Intelligence Methods in Medical Imaging for Pulmonary Tuberculosis: A Systematic Review and Meta-Analysis,” Journal of Clinical Medicine 12 (2022): 303.

[97] M. Nijiati, J. Ma, C. Hu, et al., “Artificial Intelligence Assisting the Early Detection of Active Pulmonary Tuberculosis From Chest X-Rays: A Population-Based Study,” Frontiers in Molecular Biosciences 9 (2022): 874475.

[98] S. Jamal, M. Khubaib, R. Gangwar, S. Grover, A. Grover, and S. E. Hasnain, “Artificial Intelligence and Machine Learning Based Prediction of Resistant and Susceptible Mutations in Mycobacterium tuberculosis,” Scientific Reports 10 (2020): 5487.

RIGHTS & PERMISSIONS

2025 The Author(s). Smart Medicine published by Wiley-VCH GmbH on behalf of Wenzhou Institute, University of Chinese Academy of Sciences.